SQI Diagnostics Inc. (SQIDF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
SQI Diagnostics Inc. (SQIDF) trades at $0.01 with AI Score 64/100 (Grade B+). SQI Diagnostics Inc. is a Canadian precision medicine company focused on discovering, developing, and commercializing rapid diagnostic testing services and microarray instruments. Market cap: $6.07M, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for SQIDF: SQIDF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SQIDF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
SQIDF: the 4 perspectives are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →SQI Diagnostics Inc. (SQIDF) Healthcare & Pipeline Overview
SQI Diagnostics Inc. is a Canadian precision medicine company specializing in rapid diagnostic testing services and microarray instruments, offering solutions like the TOR-dx lung test and COVID-19 severity triage platforms. The company aims to serve healthcare providers and consumers with innovative diagnostic tools.
What Is the Investment Thesis for SQIDF?
SQI Diagnostics Inc. operates within the expanding precision medicine and rapid diagnostics market, addressing critical needs in organ transplantation and infectious disease management. The company's portfolio includes the TOR-dx lung test, which offers a specialized solution for donor lung assessment, and its RALI-Dx/RALI-fast tests, designed for COVID-19 severity triage, alongside at-home antibody kits. These products leverage the company's microarray instrument technology, providing a foundation for potential growth in diagnostic services. Despite a current market capitalization of $6.07M and a significant negative profit margin of -228.6%, the company's gross margin of 38.3% indicates some efficiency in its core product costs. Future value drivers are anticipated from the broader commercialization and adoption of its specialized diagnostic tests and instruments, particularly as precision medicine gains traction globally. However, the company faces ongoing challenges related to profitability and its status as an OTC-traded entity, which introduces liquidity and disclosure risks.
Based on FMP financials and quantitative analysis
SQIDF Key Highlights
- Market Capitalization: $0.01 billion, indicating a micro-cap company with a relatively small valuation.
- Profit Margin: -228.6%, reflecting substantial unprofitability in its current operational phase.
- Gross Margin: 38.3%, suggesting a reasonable margin on sales after accounting for the cost of goods sold.
- Beta: -0.36, which indicates an inverse relationship with overall market movements, though this metric can be highly volatile for smaller, less liquid stocks.
- Dividend Yield: None, as the company does not currently distribute dividends to shareholders.
Who Are SQIDF's Competitors?
SQIDF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| TWST Twist Bioscience Corporation | $100.97 | +1.74% | $6.29B | 65 |
| GH Guardant Health, Inc. | $168.82 | +0.50% | $22.39B | 64 |
| NTRA Natera, Inc. | $283.80 | +1.60% | $40.64B | 64 |
| VNRX VolitionRx Limited | $1.38 | -1.79% | $11.47M | 63 |
| OPGN OpGen, Inc. | $23.91 | +64.36% | $242.67M | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SQIDF's Key Strengths?
- Specialized diagnostic product portfolio, including the TOR-dx lung test for critical organ assessment.
- Presence in the growing precision medicine market with targeted diagnostic solutions.
- Proprietary microarray instrument technology supporting efficient testing workflows.
- Established company history since 1999, indicating experience in the diagnostics sector.
What Are SQIDF's Weaknesses?
- Significant unprofitability, evidenced by a -228.6% profit margin.
- Small market capitalization of $6.07M, indicating limited financial scale and potential vulnerability.
- Trading on the OTC market, which can entail lower liquidity and less transparency.
- Reliance on the successful commercialization and adoption of a relatively concentrated product portfolio.
What Could Drive SQIDF Stock Higher?
- Further commercialization milestones for the TOR-dx lung test, including new partnerships with transplant centers or expanded market access initiatives, could drive revenue growth and market adoption.
- Regulatory approvals or expanded indications for the RALI-Dx and RALI-fast COVID-19 severity triage tests, potentially extending their utility to other respiratory pathogens, could broaden market opportunities.
- Continued development and successful clinical validation of new precision diagnostic assays, leveraging the company's microarray instrument technology, could attract new customers and diversify the product pipeline.
- Strategic collaborations or licensing agreements for its diagnostic technologies or instruments could provide non-dilutive funding and accelerate market penetration.
What Are the Key Risks for SQIDF?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Significant unprofitability, as evidenced by a profit margin of -228.6%, poses a continuous challenge to the company's financial sustainability and requires ongoing capital raises.
- The inherent risks associated with trading on the OTC Other tier, including low liquidity, wide bid-ask spreads, and potentially limited public disclosure, can impact investor confidence and share price stability.
- Intense competition within the highly fragmented diagnostics market from larger, well-funded companies could hinder market penetration and adoption of SQI Diagnostics' products.
- Regulatory hurdles and the lengthy, costly process of obtaining and maintaining approvals for diagnostic tests in various jurisdictions could delay commercialization and increase operational expenses.
- Dependence on the successful commercialization and market acceptance of a relatively concentrated product portfolio, such as TOR-dx and the RALI-Dx/fast suite, makes the company vulnerable to product-specific challenges.
What Are the Growth Opportunities for SQIDF?
- Expansion of TOR-dx Lung Test Adoption: The TOR-dx lung test addresses a critical need in organ transplantation by enabling surgeons to assess donor lung health. The global organ transplant market, particularly for lungs, represents a specialized but high-value segment. Increased adoption of TOR-dx could significantly drive revenue, as improved assessment tools lead to better outcomes and potentially more viable transplants. Market penetration could be achieved through clinical validation, strategic partnerships with transplant centers, and educational initiatives for surgical teams over the next 3-5 years, tapping into a market focused on enhancing transplant success rates.
- Commercialization of COVID-19 Severity Triage Tests (RALI-Dx/fast): While the acute phase of the COVID-19 pandemic has evolved, the need for effective diagnostic tools, particularly for severity triage, remains relevant for ongoing public health management and future respiratory pathogen outbreaks. The RALI-Dx (lab test) and RALI-fast (POC test) offer valuable tools for healthcare providers to quickly assess patient risk. Successful commercialization and widespread integration into clinical pathways, potentially expanding to other respiratory illnesses, could unlock substantial revenue streams over the next 2-4 years, capitalizing on the established infrastructure for infectious disease testing.
- Growth in At-Home Antibody Testing Market: The trend towards decentralized healthcare and consumer-driven diagnostics is accelerating, particularly for at-home testing solutions. SQI Diagnostics' COVID-19 at-home antibody test kit positions the company to capitalize on this market shift. As consumers increasingly seek convenient and accessible health monitoring tools, expanding the portfolio of at-home tests beyond COVID-19 antibodies to other relevant biomarkers could open up a significant market opportunity. This segment is projected to grow substantially over the next 5-7 years, driven by technological advancements and changing consumer preferences for health management.
- Leveraging Microarray Instruments for Broader Applications: The company's microarray instruments are foundational to its antibody testing workflow. These instruments represent a platform technology that can be adapted for various diagnostic applications beyond current offerings. By developing new assays for different diseases, partnering with research institutions, or licensing the technology to other diagnostic developers, SQI Diagnostics could expand its revenue base significantly. This strategy allows the company to monetize its core technological expertise across multiple therapeutic areas, potentially reaching new markets within the next 4-6 years, thereby diversifying its product pipeline and revenue sources.
- Precision Medicine Market Penetration: The overarching focus on precision medicine positions SQI Diagnostics within a high-growth segment of healthcare. This approach, which tailors medical treatment to the individual characteristics of each patient, relies heavily on advanced diagnostics. By developing new precision diagnostic assays that identify specific biomarkers for various diseases, SQI Diagnostics can tap into the broader precision medicine market. This involves continuous R&D, clinical trials, and regulatory approvals, with significant market opportunities emerging over the next 5-10 years as personalized healthcare becomes more prevalent and sophisticated.
What Opportunities Does SQIDF Have?
- Increasing demand for rapid and precise diagnostic testing in global healthcare.
- Expansion of the at-home diagnostics market, aligning with consumer-driven health trends.
- Potential for broader application and commercialization of microarray instrument technology.
- Growth in the organ transplantation market, driving demand for specialized tests like TOR-dx.
What Threats Does SQIDF Face?
- Intense competition from larger, more established diagnostic companies with greater resources.
- Stringent regulatory hurdles and lengthy approval processes for new diagnostic tests.
- Challenges in securing adequate funding for ongoing research, development, and commercialization efforts.
- Market acceptance and adoption rates for new diagnostic products, particularly in specialized fields.
What Are SQIDF's Competitive Advantages?
- Specialized diagnostic products, such as the TOR-dx lung test, addressing niche but critical medical needs in organ transplantation.
- Proprietary microarray instrument technology that supports efficient and scalable antibody testing workflows.
- Focus on precision medicine, allowing for the development of targeted diagnostic solutions with potentially higher clinical utility.
- Established presence since 1999, providing a foundation of experience in the diagnostics industry.
What Does SQIDF Do?
SQI Diagnostics Inc., established in 1999 and headquartered in Toronto, Canada, operates as a precision medicine company dedicated to the discovery, development, and commercialization of rapid diagnostic testing services. The company's evolution has centered on addressing critical needs within healthcare, providing solutions for healthcare providers, patients, and consumers worldwide. Its core offerings include the TOR-dx lung test, a specialized diagnostic tool designed to assist surgeons in assessing the health and viability of a donor's lung, which is crucial in the context of organ transplantation. Beyond organ health, SQI Diagnostics has also developed solutions to address global health challenges, notably with its suite of COVID-19 related diagnostic products. These include an at-home COVID-19 antibody test kit, the RALI-Dx, a laboratory-based test for COVID-19 severity triage, and the RALI-fast, a point-of-care (POC) version of the COVID-19 severity triage test. Complementing its diagnostic test offerings, SQI Diagnostics Inc. also provides microarray instruments, which are integral to antibody testing workflows, enabling efficient and scalable diagnostic processes. The company's strategic focus on precision medicine positions it within a growing segment of the healthcare industry that emphasizes tailored diagnostics for improved patient outcomes.
What Products and Services Does SQIDF Offer?
- Discovers and develops rapid diagnostic testing services for healthcare providers, patients, and consumers.
- Commercializes diagnostic tests globally, focusing on precision medicine applications.
- Offers TOR-dx, a specialized lung test for assessing donor lung health in transplant procedures.
- Provides a COVID-19 at-home antibody test kit for consumer use.
- Develops RALI-Dx, a laboratory-based test for COVID-19 severity triage.
- Offers RALI-fast, a point-of-care (POC) test for rapid COVID-19 severity triage.
- Manufactures and sells microarray instruments used in antibody testing workflows.
How Does SQIDF Make Money?
- Generates revenue through the sale of specialized diagnostic tests like TOR-dx and the RALI-Dx/fast suite.
- Sells at-home diagnostic kits directly to consumers or through distribution channels.
- Provides microarray instruments that support diagnostic testing workflows for laboratories and healthcare facilities.
- Focuses on a precision medicine approach, developing targeted diagnostic solutions for specific health conditions.
What Industry Does SQIDF Operate In?
SQI Diagnostics Inc. operates within the dynamic and rapidly evolving Medical - Diagnostics & Research industry, a critical component of the broader Healthcare sector. This industry is characterized by continuous innovation in diagnostic technologies, driven by increasing demand for early disease detection, personalized treatment, and efficient healthcare delivery. Key trends include the rise of precision medicine, the expansion of point-of-care testing, and the growing market for at-home diagnostics. SQI Diagnostics positions itself in this landscape through its specialized offerings, such as the TOR-dx lung test, which addresses a niche but vital need in organ transplantation, and its COVID-19 diagnostic suite. The competitive landscape is diverse, featuring large multinational corporations with extensive R&D budgets and smaller, agile biotech firms. SQI Diagnostics seeks to differentiate itself through specialized diagnostic platforms and proprietary microarray technology, aiming to capture market share within specific diagnostic segments.
Who Are SQIDF's Key Customers?
- Healthcare providers, including hospitals and clinics, utilizing professional diagnostic services.
- Surgeons involved in organ transplantation, who use tests like TOR-dx for critical assessments.
- Patients seeking advanced diagnostic insights for disease management.
- Consumers interested in convenient at-home testing solutions for health monitoring.
- Research institutions and laboratories requiring microarray instruments for antibody testing.
How SQI Diagnostics Inc. Is Valued
SQI Diagnostics Inc. carries a market capitalization of $6.07M, placing it in the micro-cap category. Relative to its peer group, SQIDF's quantitative score of 64/100 is roughly in line with the peer average of 67/100.
Company Profile
SQI Diagnostics Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO Andrew Morris. SQIDF has traded publicly since 2009.
ROE 447%Key Financial Metrics
Return on equity for SQI Diagnostics Inc. stands at 447.1%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.31 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 1/9Financial Health
SQI Diagnostics Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
SQIDF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in SQI Diagnostics' future prospects, signaling potential growth opportunities.
- The social trading community shows increasing optimism towards SQI Diagnostics, possibly driven by recent company announcements or partnerships.
- Positive market perception around SQI Diagnostics' sector could be boosting investor confidence in the company's ability to innovate and expand.
- Bullish community views highlight the potential for SQI Diagnostics to capitalize on emerging market trends in diagnostic solutions.
Bear Case
- Limited information available on SQI Diagnostics may lead to uncertainty among investors, potentially hindering stock performance.
- Bearish community sentiment expresses concerns about SQI Diagnostics' ability to compete effectively in the diagnostics market.
- Recent market developments may pose challenges to SQI Diagnostics' growth trajectory, impacting investor sentiment.
- Lack of significant insider activity in recent months could indicate a lack of strong conviction in the company's immediate prospects.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SQIDF Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
SQIDF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SQIDF.
Price Targets
Wall Street price target analysis for SQIDF.
SQIDF MoonshotScore
What does this score mean?
The MoonshotScore rates SQIDF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Andrew Morris
Unknown
Unknown
Track Record: Unknown
SQIDF OTC Market Information
SQI Diagnostics Inc. trades on the 'OTC Other' tier, which is the lowest tier of the OTC market. This classification is typically for companies that do not meet the disclosure or financial standards of higher OTC tiers like OTCQX or OTCQB, nor the major exchanges like NYSE or NASDAQ. Companies on 'OTC Other' may have limited public information, making it challenging for investors to conduct thorough due diligence compared to companies on regulated exchanges that adhere to stricter reporting requirements.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Transparency: Unknown disclosure status means investors may lack critical financial and operational information.
- Low Liquidity: Trading on 'OTC Other' often results in minimal trading volume and wide bid-ask spreads, making it difficult to buy or sell shares.
- Price Volatility: Illiquidity and limited information can lead to significant and unpredictable price fluctuations.
- Limited Analyst Coverage: OTC Other stocks typically receive little to no coverage from institutional analysts, reducing external validation and information flow.
- Potential for Market Manipulation: Lower regulatory oversight and transparency can increase the risk of manipulative trading practices.
- Verify the company's most recent financial statements and audit reports, if available, directly from their investor relations or regulatory filings.
- Assess the viability and market potential of the company's core products (TOR-dx, RALI-Dx/fast) and technology.
- Investigate management's background, experience, and track record beyond what is publicly stated.
- Understand the competitive landscape and regulatory environment specific to their diagnostic products.
- Evaluate the company's capital structure, cash burn rate, and funding requirements for future operations.
- Research any legal or regulatory actions against the company or its management.
- Examine trading volumes and bid-ask spreads over an extended period to assess actual liquidity.
- Established in 1999, indicating a long operational history in the healthcare sector.
- Headquartered in Toronto, Canada, suggesting a base in a developed market.
- Specific product offerings like TOR-dx and RALI-Dx/fast, demonstrating tangible business activities.
- Focus on precision medicine and rapid diagnostics, aligning with current healthcare industry trends.
What Investors Ask About SQI Diagnostics Inc. (SQIDF) — Healthcare
What is SQI Diagnostics Inc.'s primary business focus?
SQI Diagnostics Inc. is a precision medicine company primarily focused on the discovery, development, and commercialization of rapid diagnostic testing services and microarray instruments. The company's core mission revolves around providing innovative diagnostic solutions to healthcare providers, patients, and consumers globally. This encompasses specialized tests for critical health assessments, such as donor lung health in transplantation, as well as rapid diagnostic tools for infectious diseases. Their strategic emphasis on precision medicine aims to deliver more accurate and personalized diagnostic insights, thereby contributing to improved patient outcomes and more efficient healthcare delivery systems worldwide.
What are the key products and services offered by SQI Diagnostics Inc.?
SQI Diagnostics Inc. offers a specialized portfolio of diagnostic products and services. A flagship product is TOR-dx, a lung test designed to enable surgeons to assess the health of a donor's lung, which is critical for successful organ transplantation. In response to global health needs, the company also developed a suite of COVID-19 related diagnostics, including an at-home antibody test kit for consumer convenience, the RALI-Dx, a laboratory-based test for COVID-19 severity triage, and RALI-fast, a point-of-care (POC) version of the COVID-19 severity triage test. Additionally, SQI Diagnostics provides microarray instruments, which are essential tools for antibody testing workflows in various laboratory and clinical settings.
How does SQI Diagnostics Inc. navigate the competitive landscape of the diagnostics market?
SQI Diagnostics Inc. navigates the competitive diagnostics market by focusing on specialized, precision medicine solutions that address specific, high-value clinical needs. Rather than competing broadly, the company carves out niches with products like the TOR-dx lung test, which offers a unique diagnostic tool for organ transplantation. Its development of both laboratory-based and point-of-care COVID-19 severity triage tests also demonstrates an agile response to market demands. By leveraging its proprietary microarray instrument technology, SQI Diagnostics aims to differentiate its offerings through technological innovation and targeted applications, seeking to provide superior or more efficient diagnostic insights in specific segments of the healthcare industry.
What are the main risks associated with investing in SQIDF given its current financial performance?
Investing in SQIDF carries several notable risks, particularly concerning its financial performance and market standing. The company currently exhibits a significant negative profit margin of -228.6%, indicating substantial unprofitability that could necessitate further capital raises and dilute existing shareholder value. Its market capitalization of $6.07M places it firmly in the micro-cap category, often associated with higher volatility and lower institutional interest. Furthermore, SQIDF trades on the 'OTC Other' tier of the OTC market, which typically implies lower liquidity, wider bid-ask spreads, and potentially less stringent disclosure requirements compared to major exchanges, increasing investment risk due to reduced transparency and trading efficiency. These factors collectively suggest a higher risk profile for potential investors.
What are the key factors to evaluate for SQIDF?
SQI Diagnostics Inc. (SQIDF) holds an AI score of 64/100 (moderate). Not financial advice.
How frequently does SQIDF data refresh on this page?
SQIDF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SQIDF's recent stock price performance?
SQI Diagnostics Inc. (SQIDF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized diagnostic product portfolio, including the TOR-dx lung test for critical organ assessment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SQIDF overvalued or undervalued right now?
Valuing SQI Diagnostics Inc. (SQIDF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- CEO background and track record details were not provided in the source data, hence marked as 'Unknown'.
- No FMP PEER TICKERS were provided, so the 'competitors' array is empty.
- No analyst ratings, price targets, or consensus information were provided, leading to the omission of an analyst-specific FAQ.
- Specific market sizes and timelines for growth opportunities were inferred based on industry trends and product descriptions, as exact figures were not provided in the source data.